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Protease activityChronic ﬁbro-proliferative diseases are associated with nearly 45% of all deaths in the developed world. Matrix
metalloproteinase (MMP)mediated remodeling of the extracellular matrix (ECM) plays an important role in dis-
ease development. Degradation of type I collagen is considered having a major role in this matter. C1M is a bio-
markermeasuring type I collagen degradation fragments in blood. The aimof the current studywas to investigate
whether MMPmediated type I collagen degradation (C1M)was predictive of mortality in a large prospective co-
hort of Danish women aged 48–89 (n = 5855).
Subjects with high serumC1M showed signiﬁcant increasedmortality. The adjusted three year HRwas 2.02 [95%
CI: 1.48–2.76] for all-cause mortality, 2.32 [95% CI: 1.51–3.56] for cancer and 1.77 [95% CI: 0.98–3.17] for cardio-
vascular diseases. The adjusted nine year HR was 1.50 [95% CI: 1.28–1.75] for all-cause mortality, 1.49 [95% CI:
1.16–1.90] for cancer and 1.69 [95% CI: 1.27–2.24] for cardiovascular diseases.
High MMP-mediated type I collagen degradation was associated with increased mortality. Subjects with high
C1Mhad a 2-fold increase inmortality compared to subjectswith low levels of this collagen degradation product.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It is estimated that women in the European (EU15) countries are
expected to live approximately 80% of their lives in good health —
resulting in a healthy life expectancy up to 20% shorter than their total
life expectancy (Health and Consumer Protection Directorate-General,
2006). A major contributor to the decrease in healthy life expectancy
is chronic ﬁbroproliferative diseases such as ﬁbrosis and cancer, and
nearly 45% of all deaths in the developed world are associated with
some form of tissue remodeling disease (Wynn, 2007; Pinzani, 2008). Tis-
sue remodeling in relation to diagnosis and prognosis is therefore a hot
topic, consequent to the prevalence of diseases associatedwith this remod-
eling, following decreased healthy life expectancy and premature death.
The common denominator of ﬁbroproliferative diseases is dysregu-
lated tissue remodeling causing an accumulation of extracellularmatrix
(ECM) components in tissues of different organs (Wynn, 2007, 2008;
Wynn and Barron, 2010; Schuppan et al., 2001). The ECM consistsradation;CTX-I,CathepsinKde-
gen; ECM, Extracellularmatrix;
emiological Risk Factor study;
730 Herlev, Denmark.
bæk).
. This is an open access article undermainly of collagens, proteoglycans and glycoproteins. Collagens consti-
tute approximately 30% of all proteins in the body, with type I collagen
as the most ubiquitous collagen (Muiznieks and Keeley, 2013). Under
pathological conditions the normal remodeling balance is disturbed re-
placing original proteins of the ECMwith different matrix components, in
turn leading to an altered composition and quality of the matrix (Karsdal
et al., 2013a). Emerging evidence suggests that altered components and
post-translational modiﬁcations (PTMs) of proteins in the ECMmay both
initiate and drive disease progression (Leeming et al., 2011a).
Matrix metalloproteinases (MMPs) constitute a principal family of
enzymes involved in degradation of ECM proteins. The pathological
over-expression of MMPs results in small protein fragments holding
PTMs, which are released into the blood. These PTM fragments can
be referred to as neoepitopes or so-called ‘protein ﬁngerprints’. A
neoepitope is a protease-generated PTM, which has potential as a bio-
chemical marker of ECM remodeling (Karsdal et al., 2013b). Despite
the notion that MMP-mediated ECM remodeling is a central event in
initiation and progression of connective tissue diseases (Wynn, 2007;
Pinzani, 2008), technologies for measurement are limited in the diag-
nostic armamentarium.
Type I collagen may be measured by 4 different epitopes (CTX-I,
C1M, ICTP and PINP). Measurement of the pro-peptide of type I collagen
(PINP) is a standard marker for bone formation, while a cathepsin K de-
graded product (CTX-I) is the standard measure of bone resorptionthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
724 K. Dragsbæk et al. / EBioMedicine 2 (2015) 723–729(Rosenquist et al., 1998). Bone formation and bone resorption are
completely different and opposite directed processes, emphasizing the
need in clinical chemistry to measure the right protein in the right
way. The marker of the cross-linked carboxyterminal telopeptide of
type I collagen (ICTP), is an MMP derived intermediate conformational
epitope which has been evaluated for ECM-related diseases (Elomaa
et al., 1992). Recently we developed an ELISA assay detecting MMP-
mediated type I collagen degradation fragments in serum (termed
C1M). The competitive ELISAmeasures the end product of tissue degra-
dation, i.e. a pool of peptides/proteins all having this speciﬁc MMP-
mediated binding site as the denominator. The monoclonal antibody
recognizes a 6 amino acid sequence at position 764 in the C-terminus
of type 1 collagen (Leeming et al., 2011b). The collagen degradation
fragment is generated byMMPs 2, 9 and 13 and is destroyed by cathep-
sin K,making this a soft tissue speciﬁcmarker not originating from bone
turnover.
In the period from1999–2001 a total of 5855Danish postmenopaus-
al women participated in the large Prospective Epidemiological Risk
Factor (PERF I) study aimed at identifying risk factors associated with
age-related diseases. Serum samples originally collected in the PERF I
cohort were in the current study analyzed in relation to levels of C1M
and combined with register data from Danish national registries de-
scribing cause and time of death of the deceased part of the cohort.
We hypothesized that MMP-mediated tissue degradation of type I
collagen was predictive for mortality.
2. Methods
2.1. Study Design
The Prospective Epidemiologic Risk Factor (PERF I) studywas an ob-
servational, prospective follow-up study of Danish postmenopausal
women who had previously either participated in clinical randomized
placebo-controlled studies or were screenedwithout being randomized
for previous studies at the Center for Clinical and Basic Research (CCBR)
in either Copenhagen or Aalborg. Invitations for participationwere done
by including all subjects in the CCBR subject database regardless of their
previous medical history, ensuring no overrepresentation of subjects
with history of speciﬁc diseases. A total of 5855 Danish postmenopausal
Caucasian women aged 48-89 were enrolled in the PERF I Study from
1999–2001. The study was carried out in accordance with ICH-GCP
with study protocol approval from the local ethics committee.
2.2. Baseline Examinations
Vital signs and fasting serum samples were collected at time of en-
rollment and serum samples were stored at−80 °C for later use. Sub-
jects reported on demographic characteristics; smoking status, alcohol
consumption, physical activity and level of education as well as hyper-
tension, hyperlipidemia, cancer history and diabetes in a self-reported
questionnaire.
2.3. Outcome Variables
The primary end-points were all-cause mortality and cause speciﬁc
mortality. Date of death of the deceased sub-group of the PERF I cohort
(n=1505)was obtained from theDanish Civil Registration System and
cause of death was obtained from the National Danish Causes of Death
Registry. Registry data was obtained up to 31st December 2012 leading
to an average follow-up period of 12.1 years (11.4–13.1) for censored
subjects. Causes of death were classiﬁed according to the International
Classiﬁcation of Diseases, tenth revision (ICD10). The primary cause of
death was used for further evaluation of serum C1M levels in speciﬁc
disease groups; cardiovascular diseases (ICD10 codes I00–I99), cancer
(C00–C97), lung diseases (J00–J99), and other deaths (remaining
ICD10 codes). Subjects who were dead due to external causes (ICD10codes V01–X59) were excluded from survival analysis (n = 39). The
time of survival was deﬁned as the time from date of enrollment to
date of death or to 31st December 2012.
2.4. Type I Collagen Degradation
MMP-degraded type I collagen was measured in serum by enzyme-
linked immunosorbent assay (ELISA) as described by Leeming et al.
(2011b)(n=5629). The analytewas tested for stability andwas consid-
ered to be stable after 12 years of storage (−80 °C). In order to conﬁrm
analyte stability, 10 consecutive freeze-thaw cycles were done with no
signiﬁcant change in C1M level. Three year stability studies were per-
formed to validate detection of analyte (C1M), by measuring the same
sample in one year intervals. Moreover, the mean level of C1M found
in the present study was compared to mean levels of C1M in studies
with similar study population conducted at later time points with sam-
ple storage of shorter duration.
The cohort was divided into quartiles based on serum C1M level. Q1
(n= 1411): 26.2 ng/mL [21.2–31.3 ng/mL], Q2 (n= 1400): 35.2 ng/mL
[31.4–39.5 ng/mL], Q3 (n = 1391): 46.2 ng/mL [39.6–56.0 ng/mL], Q4
(n = 1400): 87.1 ng/mL [56.1–458.8 ng/mL].
Serum CTX-I (n = 5611) was measured by Serum CrossLaps one
step ELISA as described by Rosenquist et al. (1998).
2.5. Statistical Analysis
Statistical analysis was conducted using Medcalc® (v 12.3.0) and
SAS® (v 9.4). Data are shown as mean ± standard error mean (SEM)
if not otherwise indicated. Baseline characteristics of survivors and
dead were compared using one-way analysis of variance (ANOVA) for
numerical variables while a Chi-square test was used to compare cate-
gorical variables (Table 1).
Multivariate Cox proportional-hazard analysis was used to deter-
mine proportional hazard ratios for selected risk factors (age, BMI,
smoking, exercise, alcohol consumption, education level, hypertension,
hyperlipidemia, cancer history and diabetes) (Table 2).
Serum C1M values were normalized using log-transformation.
Univariate and multivariate Cox proportional-hazard analysis was
used to assess the relation between mortality and serum levels of C1M
(log-transformed) in the full follow up period. The adequacy of the
Cox proportional-hazard analysis was tested by checking the functional
form and the assumption of proportional hazards as described by Lin,
Wei, and Ying (Lin et al., 1993). The Kolmogorov-type supremum test
revealed no misspeciﬁcation of the functional forms for the continuous
covariates. The proportional hazard assumption was violated with log-
transformed C1M in the 12 year follow-up period. Therefore, the multi-
variate Cox proportional-hazard analysis was split in three year inter-
vals (0–3 years, 3–6 years, 6–9 years, 9–12 years) where the relation
between serum levels of C1M (log-transformed) and all-causemortality
was assessed assuming conformity with the proportional hazard as-
sumption in each three year time interval (Fig. 1). Risk factors from
Table 2 were included in themultivariate analysis. Likewise the relation
between serum levels of CTX-I (log-transformed) and all-cause mortal-
ity was assessed in each time interval (data not shown).
Hazard ratios for each quartile of serum C1M was determined by
multiplying the parameter estimate of the log-transformed C1M value
derived from the multivariate Cox proportional-hazard analysis, with
the range between the log-transformed means of serum C1M levels in
each quartile, followed by a back-transformation to the original scale
using the exponential function. The lower quartile (Q1) was used as
reference.
A Kaplan–Meier survival curve was applied to illustrate mortality
over time in the four quartiles in the full follow-up period (Fig. 2A)
and in three year time intervals (Fig. 2B–E). A log-rank test was used
to determine differences between the survival curves.
Table 1
PERF I cohort characteristics. Actual numbers are shown next to percentages.
Variable Total Alive Dead P-value
(n = 5855) (n = 4350) (n = 1505) Alive vs. Dead
Age (years) 70.8 ± 0.1 69.4 ± 0.1 74.9 ± 0.2 b0.001
BMI (kg/m2) 26.2 ± 0.1 26.3 ± 0.1 25.7 ± 0.1 b0.001
Underweight (b18.5) (%) 1.6 (90/5637) 1.1 (46/4226) 3.1 (44/1411)
Normal (≥18.5–25.0) (%) 41.6 (2343/5637) 40.5 (1713/4226) 44.6 (630/1411)
Overweight (N25.0–30.0) (%) 39.9 (2248/5637) 40.9 (1729/4226) 36.7 (518/1411)
Obese (N30.0) (%) 17.0 (956/5637) 17.5 (738/4226) 15.5 (219/1411)
Current smoking (%) 22.5 (1315/5844) 19.8 (861/4342) 30.2 (454/1502) b0.0001
Exercise (≥1 time/week, %) 68.5 (4003/5843) 72.9 (3165/4340) 55.8 (838/1503) b0.0001
Alcohol (≥7 drinks/week, %) 32.6 (1896/5812) 32.7 (1411/4317) 32.4 (485/4795) 0.9
Education (%) 0.03
Primary school 71.5 (4178/5841) 70.6 (3064/4339) 74.2 (1114/1502)
High school 21.4 (1250/5841) 22.2 (963/4339) 19.1 (287/1502)
University 7.1 (413/5841) 7.2 (312/4339) 6.7 (101/1502)
Hypertension (%) 31.0 (1807/5838) 28.9 (1252/4337) 37.0 (555/1501) b0.0001
Hyperlipidemia (%) 9.1 (530/5845) 9.4 (407/4342) 8.2 (123/1503) 0.2
Cancer history (%) 5.2 (301/5808) 4.1 (178/4313) 8.2 (123/1495) b0.0001
Diabetes (%) b0.0001
Type 1 0.7 (39/5845) 0.6 (26/4342) 0.9 (13/1503)
Type 2 2.4 (144/5845) 1.9 (83/4342) 3.9 (59/1503)
Serum C1M (ng/mL) 50.7 ± 0.5 49.8 ± 0.6 53.4 ± 1.0 0.001
Serum CTX-I (ng/mL) 0.44 ± 0.003 0.44 ± 0.004 0.44 ± 0.007 0.7
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assess levels of serum C1M (log-transformed) in the time interval
from 0–9 years (Fig. 3). Risk factors from Table 2 were included in the
multivariate analysis.
Hazard ratios were determined for deaths caused by cancer, cardio-
vascular diseases, lung diseases and other types of death for subjects
with serum C1M level in the upper quartile (Q4) versus subjects in
the lower quartile (Q1) in time intervals 0–3 years and 0–9 years
(Fig. 4). Hazard ratios for cause-speciﬁc diseases were calculated solely
on the contribution of deaths with the speciﬁc diagnose. The remaining
part of the deceased population was excluded from the analysis.3. Results
3.1. PERF I Cohort Characteristics
Table 1 summarizes baseline characteristics of the PERF I cohort
stratiﬁed in alive and dead subjects, 12 years after initiation of theTable 2
Hazard ratios for risk factors associated with mortality.
All hazard ratios are mutually adjusted.
Variable Multivariate analysis
Hazard
ratio
95% conﬁdence
interval
P-value
Age (years) 1.13 1.12 to 1.14 b0.0001
BMI (kg/m2)
Underweight (b18.5) 1.59 1.16 to 2.18 0.004
Normal (≥18.5–25.0) Reference
Overweight (N25.0–30.0) 0.90 0.80 to 1.02 0.1
Obese (N30.0) 0.86 0.73 to 1.01 0.08
Current smoking (yes/no) 1.90 1.69 to 2.14 b0.0001
Physical inactivity (vs. ≥1 time/week) 1.52 1.36 to 1.70 b0.0001
Alcohol (≥7 drinks/week) 1.07 0.95 to 1.20 0.3
Education
Primary school Reference
High school 0.91 0.79 to 1.04 0.2
University 0.90 0.73 to 1.11 0.3
Hypertension (yes/no) 1.18 1.05 to 1.32 0.004
Hyperlipedemia (yes/no) 1.07 0.88 to 1.30 0.5
Cancer history (yes/no) 1.86 1.53 to 2.26 b0.0001
Diabetes (no/Type 1/Type 2)
Type 1 1.52 0.88 to 2.62 0.1
Type 2 1.88 1.41 to 2.51 b0.0001study. The mean age for the total population was 70.8 years (49.7–
88.8). From study entry until 31st December 2012 a total of 1505 sub-
jects died. The age in the deceased subgroup was signiﬁcantly higher
compared to the group of subjects still alive. The entire cohort was
characterized by being slightly overweight (BMI 26.2 ± 0.1) with the
deceased subgroup having a signiﬁcantly lower BMI compared to the
subjects still alive (25.7 ± 0.1 versus 26.3 ± 0.1) (p b 0.001). The living
group was characterized by less smokers (19.8% versus 30.2%), subjects
with slightly higher education level (22.2% versus 19.1% high school ed-
ucated), and a larger proportion of physically active subjects (72.8% ver-
sus 55.7%). In the cohort 33% consumed more than 7 drinks/week and
the proportion of alcohol-consumers drinking ≥7 drinks/week was
equal in the living and the deceased group. The deceased group was
characterized by having a signiﬁcantly higher proportion of hyperten-
sive and diabetic subjects, whereas the proportion of subjects with hy-
perlipidemia did not differ between the two groups. The proportion of
subjects with a history of cancer was signiﬁcantly larger in the deceased
part of the cohort (8.2% versus 4.1%).
The serum C1M level was signiﬁcantly higher (p= 0.001) in the de-
ceased part of the cohort compared to those still alive, while no signiﬁ-
cant difference was seen in serum levels of CTX-I (p = 0.7).
3.2. Risk Factors for All-cause Mortality
A multivariate Cox proportional-hazard model was used to assess
the independent contribution of risk factors (age, smoking, BMI, physi-
cal inactivity, alcohol consumption, education level, hypertension, hy-
perlipidemia, cancer history and diabetes) to mortality in the cohort
(Table 2).
All risk factors, except for education level, alcohol consumption (≥ 7
drinks/week), and hyperlipidemia, were associated with mortality.
3.3. Survival
A multivariate Cox proportional-hazard analysis was used to assess
hazard ratios for C1M, after adjusting for risk factors listed in Table 2,
in different time intervals from blood sampling until time of death.
This was done to determine the predictive nature of C1M (Fig. 1).
An increase in mortality with increasing C1M was observed in the
0–3 year interval. This will introduce a “survivor effect” when applying
the three year stratiﬁcation approach in the remaining time intervals, as
it will drive the high risk group towards the low risk group over time.
N HR (95% CI)
Q1 1205 124 1 [Reference]
Q2 1193 134 0.96 (0.91-1.02)
Q3 1153 131 0.93 (0.84-1.04)
Q4 1100 110 0.86 (0.68-1.08)
N HR (95% CI)
Q1 1350 68 1 [Reference]
Q2 1337 59 1.07 (1.00-1.15)
Q3 1327 63 1.14 (1.00-1.30)
Q4 1302 83 1.32 (1.00-1.74)
HR (95% CI) for quartiles of C1M
1 2 30.6
HR (95% CI) for quartiles of C1M
1 2 30.6
HR (95% CI) for quartiles of C1M
1 2 30.6
HR (95% CI) for quartiles of C1M
1 2 30.6
N HR (95% CI)
Q1 1383 33 1 [Reference]
Q2 1371 34 1.19 (1.10-1.28)
Q3 1364 37 1.39 (1.20-1.62)
Q4 1369 67 2.02 (1.48-2.76)
N HR (95% CI)
Q1 1282 77 1 [Reference]
Q2 1278 85 1.09 (1.03-1.15)
Q3 1264 111 1.18 (1.06-1.31)
Q4 1219 119 1.41 (1.12-1.78)
0 - 3 years
3 - 6 years
6 - 9 years
9 - 12 years
A
B
C
D
Fig. 1. Hazard ratios with 95% CI for all-cause mortality in quartiles (Q1–Q4) of C1M. A:
0–3, B: 3–6, C: 6–9 and D: 9–12 years. Values are adjusted for age, BMI, smoking, alcohol
consumption, physical inactivity, education level, hypertension, hyperlipidemia, cancer
history and diabetes.
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9–12 year intervals, a trend towards an increase in hazard ratio from
the lowest quartile (Q1) to the upper quartile (Q4) was observed in all
time intervals from 0–9 years. A 2-fold increase in risk of mortality
was observed in the interval from 0–3 years (Fig. 1A, HR 2.02 [95% CI:
1.48–2.76]) for subjects with serum C1M levels in the upper quartile
(Q4) compared to the lowest quartile (Q1). The same tendency, howev-
er non-signiﬁcant, was seen in the interval from 3–6 years (Fig. 1B, HR
1.32 [95% CI: 1.00–1.74]) and from 6–9 years (Fig. 1C, HR 1.41 [95% CI:
1.12–1.78]). In the interval from 9–12 years no signiﬁcant change in
hazard ratio could be observed between the four quartiles (Fig. 1D).
Contrary, the other type I collagen degradation product (CTX-I) was
not found to be a predictor of all cause mortality in neither of the three
year intervals from the multivariate Cox proportional-hazard model
(data not shown).
A Kaplan–Meier survival curve was applied to illustrate survival
over time (Fig. 2A). Part of the cohort with serum C1M levels in the
upper quartile (Q4) had a decreased survival probability compared
to the three other quartiles in the entire 12 year follow-up period
(p = 0.0001). No signiﬁcant difference was seen comparing the lowest
quartile (Q1) and the two middle quartiles (Q2 and Q3) in the full
follow-up period. Pooled data from Q1–Q3 was used for determining
thedifference inmortality compared to theupper quartile (Q4). A signif-
icant difference in mortality was seen in time intervals from 0–9 years;
0–3 years (p = 0.0001), 3–6 years (p = 0.01), and 6–9 years (p =
0.002) (Fig. 2B–D). No difference in mortality was found in the time in-
terval from 9–12 years (p = 0.38, Fig. 2E).
ACoxproportional-hazard analysiswasused to assess themortality risk
in part of the follow-up period where an increase in hazard ratio wasobserved (0–9 year) (Fig. 3). In the univariate Cox proportional-hazard
analysis a 59% increased risk of mortality (HR 1.59 [95% CI: 1.38–1.85])
was found, when comparing Q4 to Q1 (Fig. 3A). The increase in mortality
risk was 50% (HR 1.50 [95% CI: 1.28–1.75]) within the nine year follow-
up period when a multivariate Cox proportional-hazard analysis was ap-
plied accounting for risk factors known to impact mortality (Fig. 3B).
3.4. Cause Speciﬁc Mortality
Cause speciﬁc mortality was assessed in part of the cohort with
serum C1M levels in the upper quartile (Q4) versus subjects with
serum C1M levels in the lowest quartile (Q1). A multivariate Cox
proportional-hazard analysis was used to assess the cause speciﬁc mor-
tality risk in the time intervals 0–3 years and 0–9 years (Fig. 4).
In themultivariate Cox regression-analysis, the hazard ratiowas 2.32
[95% CI: 1.51–3.56] for cancer, 1.77 [95% CI: 0.98–3.17] for cardiovascu-
lar diseases, 1.67 [95% CI: 0.48–5.84] for lung diseases, and 1.77 [95% CI:
0.71–4.42] for other deaths within the 0–3 year interval (Fig. 4A).
In the 0–9 year follow-up interval, the hazard ratio was 1.49 [95% CI:
1.16–1.90] for cancer, 1.69 [95% CI: 1.27–2.24] for cardiovascular dis-
eases, 1.09 [95% CI: 0.63–1.88] for lung diseases, and 1.63 [95% CI:
1.19–2.24] for other deaths (Fig. 4B).
4. Discussion
We have identiﬁed MMP-mediated type I collagen degradation
(C1M) as an independent risk factor for all-cause mortality. Contrary,
we found no association between cathepsin K degraded type I collagen
(CTX-I) and all-cause mortality. This suggests that speciﬁcally MMP-
mediated tissue degradation of type I collagen is associated with
mortality.
We found a 2-fold increase inmortality risk in the ﬁrst three years of
follow-up and a 1.5-fold increase was observed with nine year follow-
up time in individuals having high MMP-mediated type I collagen deg-
radation compared to individuals with a low serum level of this type I
collagen degradation marker.
During pathological remodeling of the ECM excessive levels of
tissue- and pathology-speciﬁc turnover products are released into the
circulation consequently becoming biomarkers. In the present study
degradation of type I collagen was measured as a marker for tissue
degradation as it is assumed to be a key player in ECM remodeling.
Our results emphasize that the enzymatic processing is important
since only the MMP-mediated type I collagen degradation was predic-
tive of mortality, not cathepsin K degraded type I collagen. Increased
serum C1M levels have previously been shown to be associated with
diseases in which chronic inﬂammation is a key driver, such as ankylos-
ing spondylitis (Bay-Jensen et al., 2012), osteoarthritis (Siebuhr et al.,
2014), rheumatoid arthritis (Bay-Jensen et al., 2014), and different
types ofﬁbrosis (Leeming et al., 2012, 2013)- diseaseswhich are all con-
tributing to a decreased healthy life expectancy and ultimately death.
The prognostic nature of C1M was assessed by dividing the follow-
up period into three year intervals. A 2-fold increase in risk of mortality
was determinedwithin the ﬁrst three years of the follow up period. The
increase in mortality with increasing C1M observed in the 0–3 year in-
terval introduce a “survivor effect” when applying the three year strat-
iﬁcation approach. This may explain why the HRs decrease over time,
driving the associations towards the null hypothesis in the remaining
time intervals (3–12 years). The observed potential association in the
intermediate time spans (3–6 and 6–9 years) is therefore very likely,
but presumably underestimated since the “survivor effect” will drive
the high risk group towards the low risk group over time. Despite this,
we believe that C1M may predict an increased risk of mortality up to
nine years prior to death for subjects with C1M levels in the upper
quartile. A 1.5-fold hazard ratio was determined for the combined
0–9 year interval (Fig. 3). The higher risk in the 0–3 year interval under-
lines the understanding that an event, in this case death, is easier to
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727K. Dragsbæk et al. / EBioMedicine 2 (2015) 723–729predict closer to time of occurrence. Subjects with high MMP-mediated
type I collagen degradation may therefore be predisposed to a de-
creased life expectancy based solely on their degree of type I collagen
degradation.
The PERF I cohort comprised slightly overweight elderly women at
risk of developing commonwestern-lifestyle diseases such as type II di-
abetes, hypertension and hyperlipidemia. These lifestyle diseases affect
many tissues and organs resulting in chronic low grade inﬂammation
possibly following ﬁbroproliferative changes to the ECM and thereby
collagen degradation. The most prevalent primary causes of death inthe PERF cohort were cancer and cardiovascular diseases accounting
for 34% and 27% of all deaths, respectively. Similarly, the two largest
causes of death for women aged 70–74 in the EU, as reported in the
European Health Report, are cancer and cardiovascular diseases ac-
counting for 37% and 42% respectively (WHO, 2013). High MMP-
mediated type I collagen degradation was associated with both cancer
and cardiovascular mortality. At ﬁrst glance, two markedly different
diseases, however with increased tissue turnover being a common de-
nominator of both diseases. The risk of dying from cancerwas increased
2.3-fold in theﬁrst three years of follow-up and an approximate 1.5-fold
HR (95% CI), adjusted
0.6 0.8
HR (95% CI), unadjusted
1 21 2 30.6
N HR (95% CI)
Q1 1411 188 1 [Reference]
Q2 1400 185 1.12 (1.08-1.16)
Q3 1391 217 1.25 (1.16-1.34)
Q4 1400 280 1.59 (1.38-1.85)
N HR (95% CI)
1383 178 1 [Reference]
1371 178 1.10 (1.06-1.15)
1364 211 1.21 (1.13-1.30)
1369 269 1.50 (1.28-1.75)
BA
Fig. 3. Hazard ratios with 95% CI for all-cause mortality in quartiles (Q1–Q4) of C1M with nine year follow-up. A: unadjusted, B: adjusted. Adjusted values are corrected for age, BMI,
smoking, alcohol consumption, physical inactivity, education level, hypertension, hyperlipidemia, cancer history and diabetes.
728 K. Dragsbæk et al. / EBioMedicine 2 (2015) 723–729increasewas observedwithin the nine year follow-up period in individ-
uals having high MMP-mediated type I collagen degradation. These
ﬁndings correspondwell with the association between ECM remodeling
and tumorgenesis (Bonnans et al., 2014; Lu et al., 2012) as ECM remod-
eling in cancer leads to a dysregulation in tumor growth, inﬂammation,
tissue invasion, and metastasis (Kessenbrock et al., 2010).
In addition, risk of dying from cardiovascular diseases was increased
1.8-fold in theﬁrst three years of follow-up and an approximate 1.7-fold
increase was observed with nine year follow-up period in individuals
having high MMP-mediated type I collagen degradation. Atherosclero-
sis is a typical hallmark of cardiovascular diseases leading to a distur-
bance of the ECM homeostasis in the artery wall combined with low-
grade inﬂammation. This results in a disrupted structure of the ECM of
the artery wall, ultimately leading to cardiovascular disease and fatal
events (Hobeika et al., 2007; Raines, 2000; Galis and Khatri, 2002).
Other tissue turnover markers have been associated with mortality; al-
beit not type I collagen degradation byMMPs. P3NP, a formationmarker
of type III collagen, was associated with all-cause mortality in the
Framingham study (Velagaleti et al., 2010). Endostatin, a degradation
fragment of type XVIII collagen, was associated with all-cause, cancer
and cardiovascular mortality in two independent cohorts from Sweden
(Ärnlöv et al., 2013).
Degradation and formation are interlinked in the tissue turn-
over balance, making both processes equally important. Determining
the better biomarker is therefore not easy. Formation markers, like
P3NP, are generated in all tissues comprising type III collagen.0
0
N HR (95% CI)
All 1369 269 1.50 (1.28-1.75)
Cancer 1209 109 1.49 (1.16-1.90)
CVD 1183 83 1.69 (1.27-2.24)
Lung 1116 16 1.09 (0.63-1.88)
Other 1161 61 1.63 (1.19-2.24)
N HR (95% CI)
All 1369 67 2.02 (1.48-2.76)
Cancer 1337 35 2.32 (1.51-3.56)
CVD 1324 22 1.77 (0.98-3.17)
Lung 1305 3 1.67 (0.48-5.84)
Other 1309 7 1.77 (0.71-4.42)
A
B
Fig. 4.Hazard ratios with 95% CI for all-cause mortality and cause speciﬁc mortality (cancer, car
(Q4) in time intervals 0–3 years (A) and 0–9 years (A). Hazard ratios are adjusted for age, BMI
lipidemia, cancer history and diabetes.However, when measuring a MMP-mediated degradation product,
like C1M, it is a prerequisite that the protease is co-expressed in the af-
fected tissue, making this a speciﬁc marker for pathologic tissue turn-
over. When assessing mortality, MMP-mediated type I collagen
degradationmay possibly either reﬂect a consequence or a cause of dis-
ease leading to mortality (Karsdal et al., 2010). In order to further an-
swer this question, it would be beneﬁcial to have sequential
measurements of C1Mwhich couldmore closely relate diagnosis of dis-
ease rather than early prognosis. In the current study it can only be spec-
ulated that some individuals may be predisposed for an increased
degradation, potentially making them prone to certain diseases and
eventually premature death.
Increased serum levels of C1M have shown to be associated with
pain and progression of disease in rheumatoid arthritis, and conversely,
a decrease by anti-inﬂammatory modulation (anti-interleukin-6) of
more than 35%was associatedwith protection fromdisease progression
(Siebuhr et al., 2013). This may suggest that attenuation of high remod-
eling by intervention could be associated with increased life-span. The
relation between inﬂammation and tissue turnover is of particular in-
terest. In autoimmune diseases like rheumatoid arthritis CRP and C1M
have been proven to be highly correlated (Siebuhr et al., 2013). In dis-
eases like ﬁbrosis, inﬂammation may initiate disease, however once
present ﬁbrosis can progress without inﬂammation (Trautwein et al.,
2015). The nature and extent of inﬂammation and ECM remodeling
are therefore likely to be very different in different diseases and stages
within the same disease. Although this current study identiﬁed theHR (95% CI), adjusted
0.8 546.
HR (95% CI), adjusted
1 2 3
1 2 3 56. 40.8
diovascular diseases, lung diseases and other diseases) for the upper quartile of the cohort
, smoking, alcohol consumption, physical inactivity, education level, hypertension, hyper-
729K. Dragsbæk et al. / EBioMedicine 2 (2015) 723–729prognostic importance of C1M assessment in serum, it remains to be
shown whether lowering this marker can result in a reduction of the
mortality risk.
Interpreting biochemical markers found in serum is associated with
many limitations, as several different tissues at different rates may pro-
duce and thus contribute to the total pool of molecular marker. Type I
collagen is highly abundant in many tissues throughout the body, and
an increase in the serological levels of C1M is a hallmark of several
ﬁbroproliferative diseases. Further studies on disease-speciﬁc contribu-
tions to the total pool of ECM remodeling are therefore needed. Impor-
tantly however,measuring increased levelsmay assist in identifying the
sub-groups predisposed for increased ECMremodeling. This could aid in
early diagnosis of subjects with high tissue turnover, leading to connec-
tive tissue diseases, which may beneﬁt from increased medical atten-
tion thereby potentially increasing their lifespan.
This cohort is solely comprised of Danish postmenopausal women
and further generalization to other demographics needs to be investi-
gated. However, the risk factors identiﬁed in the Cox proportional-
hazard analysis (smoking, alcohol consumption, physical inactivity,
education level, hypertension, hyperlipidemia and diabetes) had similar
associations to risk factors found in the Nurses' Health Study, a cohort of
middle-aged women (Baer et al., 2011).
Moreover, as in other epidemiological studies, ﬁndings in the
present study may be affected by selection bias caused by possible
over-representation of relatively healthy subjects in the cohort. One
could however argue that this would tend to draw the results in a direc-
tion towards the null hypothesis and therefore cannot explain our pos-
itive results.5. Conclusion
We found that increased MMP-mediated tissue degradation, as an
independent risk factor, was associated with a 2-fold increase in all-
cause mortality within three years of follow-up and a 1.5-fold increase
in all-cause mortality up to nine years prior to death.
MMP-mediated tissue degradationmay be an important predisposi-
tion for cause of disease and subsequent mortality.Author contributions
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